This is true but I am happy to wait as long as necessary for the investment in the sales, marketing and production infrastructure. I have full confidence that they are doing all the right things, have a plan and are executing it efficiently. Its really important to really own the production so they can control the quality of the product and reap all the benefits of it. Plus, this sets them up for easily transitioning to the development and production other cardiovascular applications in the future. IMO we are seeing the beginning of a snowball effect.
Cardiocel other applications, page-23
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.26 | $10.35 | $9.80 | $295.8K | 29.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22 | $9.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 2758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |